M ycobacterium tuberculosis (Mtb) can persist in multiple intracellular niches within human macrophages (1) . Given that total host cell accumulation does not necessarily correlate with antibiotic efficacy against intracellular pathogens, we hypothesized that efficacy is modulated by partitioning of compounds within the host cell (2) . The antitubercular antibiotic bedaquiline (BDQ) is highly lipophilic (3, 4) , a trait associated with permeability through tissue at the expense of nonspecific binding and host sequestration (5) (6) (7) . We tested whether efficacy is linked to the accumulation of the drug in intracellular compartments.
To characterize the intracellular distribution of BDQ, we infected human monocyte-derived macrophages (hMDMs) with Mtb for 48 hours, giving bacteria time to enter multiple subcellular compartments (1) . Macrophages were treated with 2.5 mg/liter BDQ for 24 hours, fixed, and imaged by correlative electron microscopy (EM) and ion microscopy (IM) (8) Because BDQ contains a bromine atom, we could determine its localization by measuring the intensity of the 79 Br signal (Fig. 1 , A to C). Control macrophages treated only with the solvent carrier did not contain 79 Br, confirming that the signal was specific ( fig. S1C) . Some of the 79 Br signal is derived from primary metabolites of BDQ, which are also active against Mtb (9) . BDQ accumulated heterogeneously in Mtb within macrophages, even between neighboring bacteria (Fig. 1A) . BDQ was found in Mtb in a variety of intracellular environments, including a membranous vacuole and a lysing necrotic macrophage (Fig. 1, A and B) , a known mycobacterial niche (1) .
We also observed Mtb interacting with host lipid droplets (LDs), as previously reported (10), and found the LDs to be highly enriched with antibiotic (Fig. 1C) . No characteristic ion signal exists for LDs, so to confirm the organelle identity, we stained an infected sample with the neutral lipid dye BODIPY 493/503 and imaged it with correlative light, electron, and ion microscopy (CLEIM, Fig. 1D ). Live-cell imaging before fixation showed that the bacteria were intracellular before antibiotic treatment, confirming that they absorbed BDQ from within the host cell (movie S1). Liquid chromatography-mass spectrometry (LC-MS) quantification of BDQ from unfixed macrophages treated with pradigastat (11) , an inhibitor of diacyglycerol O-acyltransferase 1, to inhibit LD formation or with oleate to induce it confirmed LD as the primary reservoir of intracellular BDQ (Fig. 1E) . This validated the CLEIM protocol in preserving the antibiotic distribution during processing.
To organelles, particularly mitochondria, reflecting reports that BDQ inhibits mammalian adenosine triphosphate (ATP) synthase (12) (Fig. 1, F and G). A similar distribution of BDQ was observed at a much lower concentration of antibiotic (0.04 mg/liter); however, at this level, the 79 Br signal was only marginally detectable ( fig. S1D ).
Lipid-laden foamy macrophages are a hallmark of tuberculosis pathogenesis (13) . Because LDs were the primary site of BDQ accumulation in the host, we investigated the interactions between LDs and Mtb in human macrophages. As expected, Mtb exposure induced host LD proliferation (10, 14, 15) , even in uninfected "bystander" macrophages ( Fig. 2A and fig. S2A ). LC-MS analysis found that 123 triacylglycerides (TAGs), together with two cholesterol esters and four ceramides, were more abundant in infected macrophages. This included many TAGs containing odd-chain fatty acids, which are associated with Mtb virulence (16) (Fig. 2B and fig. S3 ). Confocal microscopy revealed extreme heterogeneity in both bacterial and LD burdens (Fig. 2C) . Because intracellular mycobacteria consume host LDs as a carbon source (17, 18) , we investigated the temporal progression of LD induction and consumption. Live-cell imaging showed that, as Mtb grows intracellularly, LD proliferation outweighs consumption for the first~48 hours of infection, before consumption eventually reduces the number of LDs ( Fig. 2D; fig. S2 , D and E; and movies S2 and S3).
Transmission EM (TEM) showed extensive physical contacts between LDs and Mtb or tight Mtb-containing vacuoles ( fig. S2C ). We also found that the LD surface protein Perilipin 2 (PLIN2), known to associate with intracellular M. marinum (19) , labeled 3.8% of Mtb 96 hours after infection (95% confidence interval 1.86 to 6.59, n = 4 donors) (Fig. 2E) . (Fig. 2F and movie S4) .
We next investigated whether LDs sequestered or transferred BDQ to Mtb. We preloaded macrophages with antibiotic and then infected them with Mtb. The distribution of BDQ was indistinguishable from that of samples treated after infection (Fig. 3, A and B) , thus BDQ can be transferred from a host reservoir to Mtb. Cotreatment with pradigastat, which reduces LD levels, significantly reduced BDQ abundance in Mtb and inhibited preloading ( fig. S2B and Fig. 3,  A and B) . Therefore, LDs accumulate a BDQ pool that can be transferred to bacteria, although they are not absolutely required for BDQ access to Mtb. The induction of LD formation by the addition of the fatty acid oleate did not prevent BDQ transfer to Mtb (Fig. 3, A and B) . LD may thus act more as an accessible reservoir than as a sequestrator of BDQ. Damage to the phagosomal membrane and escape into the cytosol is an important feature of Mtb virulence (22) . Therefore, we compared macrophages infected with wild-type Mtb and the DRD1 strain, which lacks the ESX-1 type VII secretion system required for cytosolic access (Fig. 3C) . Both strains showed a similar BDQ signal, thus BDQ can be transferred to phagosomal bacteria. Furthermore, we infected macrophages with formaldehyde-killed Mtb to test whether BDQ uptake was actively controlled by bacteria. Killed bacteria showed a nonstatistically significant upward trend in BDQ signal (Fig. 3D) . We also treated macrophages with the proposed efflux-pump inhibitor verapamil (23) , which slightly reduced BDQ accumulation; however, its mechanism of action has recently been called into question (24) (Fig. 3D) .
Although LDs were not essential for BDQ transfer to Mtb, we hypothesized that they may enhance antibiotic efficacy. In this case, BDQ will accumulate over time in the host macrophage LDs, increasing the effective BDQ dose for bacteria that later consume them. To study marginal changes in BDQ efficacy, we developed two intracellular antibiotic activity assays in which Mtb replication was measured by high-content confocal microscopy ( fig. S4A ). BDQ concentrations were selected on the basis of their ability to partially limit Mtb growth ( fig. S4, B and C) . Inhibitors targeting lipid metabolism enzymes, as well as low-density lipoproteins, were screened for their ability to modulate macrophage LD burden. Only DGAT-1 inhibitors and oleate were found to be effective and nontoxic ( fig. S4, D to  H) . A multiplicity of infection of 1 was used to avoid host cell necrosis, which would expose Mtb to extracellular BDQ.
Inhibition of LD formation by pradigastat, A922500, and T863 reduced antibiotic efficacy in macrophages treated with 2.5 mg/liter BDQ, whereas induction with oleate significantly increased BDQ efficacy (Fig. 4, A and B) , therefore LDs facilitated antibiotic effectiveness. Preloading of macrophages with BDQ before infection results in a similar level of inhibition, indicating an accessible intracellular BDQ reservoir (Fig. 4,  A and C) . BDQ has a physiological terminal halflife of 6 months (25) . Therefore, BDQ stored in LDs may be accessible well after the patient has stopped treatment. Furthermore, oleate induction of LDs enhanced the efficacy of preloaded BDQ at a marginally effective concentration (0.25 mg/liter), suggesting that these macrophages contained a larger antibiotic reservoir. Conversely, pretreatment with pradigastat reduced the efficacy of 2.5 mg/liter BDQ. By separating macrophages by LD and Mtb burden at the single-cell level, we observed that BDQ disproportionately depleted the high-LD/ high-Mtb subpopulation compared with low-LD/high-Mtb macrophages ( fig. S4I ). This pattern held when the LD burden in the population (26) , and these results will inspire a reevaluation of the parameters used to screen drug candidates and the importance of subcellular pharmacokinetics to understanding antibiotic efficacy.
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